Serenity Study - How to See Antithrombotic Therapy in Advanced Cancer?

Join Dr Justin Jagosh (University of the West of England, UK), Dr Jamilla Goedegebuur (Leiden University Medical Center, NL), Elin Baddeley Research Associate (Cardiff University, Cardiff, UK), Dr Lisanne van ‘t Walderveen (Leiden University Medical Center, NL), Dr Sebastian Szmit (Medical Centre of Postgraduate Education, PL)  Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) as they explore the vital role of cardio-oncology in managing cardiovascular implications of antithrombotic therapy in cancer patients, ensuring that both cancer and heart health are effectively addressed in treatments.

The experts will discuss how to approach treatment decisions, the challenges in managing these patients, and what the results of this study mean for the future of clinical care.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.